Understanding the Early Cancer Detection Market: Size, Growth, and SpotitEarly's Position

Receiving a cancer diagnosis at an advanced stage changes everything: treatment options narrow, protocols grow heavier, and the chances of survival can fall from above 90% to as low as 12%, depending on which stage the cancer is caught. In many cases, it is a question of timing and of the tools available. This is the problem SpotitEarly was built to address, with a non-invasive approach designed to make early cancer detection accessible.

The Cost of Detecting Cancer Too Late

This pattern, in which survival drops sharply as cancer is caught later, holds across many cancer types. And the screening system is structured to miss many of them. Today, 57% of cancers diagnosed in the United States have no recommended screening test, and those cancers account for roughly 70% of cancer-related deaths.

The economic dimension follows directly from the clinical one. Late-stage cancer treatment costs between 1.6 and 7.7 times more than early-stage treatment, depending on the cancer type. A system that detects cancer later does not only cost patients more in suffering. It costs the healthcare system more in every measurable way.

A Market Built Around an Unsolved Problem

The scale of the opportunity in early cancer detection reflects the scale of the unmet need. The global cancer diagnostics market was valued at around $109.6 billion in 2024 and is projected to reach $155.1 billion by 2030, a compound annual growth rate of 6.14%, with North America representing approximately 41% of the total.

Within that broader market, the fastest-growing segment is Multi-Cancer Early Detection (MCED). The MCED market was valued at $1.12 billion in 2024 and is projected to reach $2.86 billion by 2030, a compound annual growth rate close to 17%. That growth reflects a shift that is already underway: from today's single-cancer screening toward tests capable of detecting multiple cancer types at once, targeting precisely the coverage gaps where today's protocols fall short.

Better Outcomes, Lower Costs: Why Insurers Are Paying Attention

The clinical and economic case for earlier detection has not gone unnoticed by insurers. Cancer accounts for roughly 50% of life insurance death claims. The logic for any payer, health or life, is reducing the price of treating a metastatic cancer that could have been found at an early stage.

Some payers are already investing in this sector. Curative Insurance offers Galleri, Grail's MCED blood test, at zero copay and zero deductible as a member benefit. Munich Re has also partnered with Grail to extend MCED access to their life insurance policyholders.

On the policy side, the U.S. government formalized its support by signing H.R. 842, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, into law on February 3, 2026. Beginning in 2028, it opens Medicare coverage for FDA-approved MCED tests for eligible beneficiaries.

How the is the early detection market is Scaling: What the Leaders Show

Two companies offer a concrete picture of where the MCED market is heading. Both rely on liquid biopsies, blood-based tests that analyze DNA shed by tumors.

Grail, whose Galleri is among the most studied MCED products on the market, reported $147.2 million in revenue for 2025, up 17% year over year, with 2026 Galleri revenue growth guided at 22% to 32%. Independent analysts project Grail's revenue approaching $232 million by 2028. A recent NHS trial did not meet its primary endpoint, but it did report a four-fold higher cancer detection rate when Galleri was added to standard screening.

Exact Sciences launched its multi-cancer, Cancerguard at $689 per test in September 2025, and announced a pending acquisition by Abbott in November 2025. The company has publicly targeted tripling the number of individuals it screens by 2027.

This level of revenue, capital deployment, and strategic backing reflects how seriously the category is now taken.

Where SpotitEarly Fits In the Early Cancer Detection Market

SpotitEarly is strategically positioned to address a significant portion of this growing market. The test is simple, non-invasive and uses an at-home breath collection kit, removing the need for a clinic visit or a blood draw. The platform is designed as a pre-screening layer, complementing existing protocols rather than replacing them. From a single breath sample, our bio-AI hybrid platform, LUCID, analyzes the signal of multiple cancer types, offering an efficient path to broader coverage. We are initially targeting Breast Cancer in the North American market and plan to expand to additional cancers in the near future. Our Rainbow Study, a peer-reviewed prospective trial published in Scientific Reports (Nature Publishing Group), reported 93.9% sensitivity for early-stage detection across the four target cancer types.

The Bottom Line

The early cancer detection market is large, growing, and backed by a new Medicare law and growing insurer interest. But behind every market projection is a simpler reality: catching cancer earlier saves lives, reduces suffering, and costs less. SpotitEarly's non-invasive, breath-based pre-screening test is designed to make that earlier detection accessible to more people, regardless of where they live or whether they have a clinic nearby. As always, any decisions about your personal screening should be discussed with your physician.